Anti-leukemic effects of the V-ATPase inhibitor Archazolid A
Metrics: PDF 1517 views | HTML 2707 views | ?
Siwei Zhang1, Lina S. Schneider1, Binje Vick2,4, Michaela Grunert2, Irmela Jeremias2,3,4, Dirk Menche5, Rolf Müller6, Angelika M. Vollmar1 and Johanna Liebl1
1 Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University, Munich, Germany
2 Department of Gene Vectors, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
3 Department of Oncology/Hematology, Dr. von Haunersches Kinderspital, Munich, Germany
4 German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
5 Kekulé-Institut für Organische Chemie und Biochemie der Universität Bonn, Bonn, Germany
6 Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Department of Pharmaceutical Biotechnology, Saarland University, Saarbrücken, Germany
Johanna Liebl, email:
Keywords: Archazolid, leukemia, natural compounds
Received: May 20, 2015 Accepted: October 07, 2015 Published: October 19, 2015
Prognosis for patients suffering from T-ALL is still very poor and new strategies for T-ALL treatment are urgently needed. Our study shows potent anti-leukemic effects of the myxobacterial V-ATPase inhibitor Archazolid A. Archazolid A reduced growth and potently induced death of leukemic cell lines and human leukemic samples. By inhibiting lysosomal acidification, Archazolid A blocked activation of the Notch pathway, however, this was not the mechanism of V-ATPase inhibition relevant for cell death induction. In fact, V-ATPase inhibition by Archazolid A decreased the anti-apoptotic protein survivin. As underlying mode of action, this work is in line with recent studies from our group demonstrating that Archazolid A induced S-phase cell cycle arrest by interfering with the iron metabolism in leukemic cells. Our study provides evidence for V-ATPase inhibition as a potential new therapeutic option for T-ALL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.